Roles
- Professor
- Associate Director, Clinical Research
- Director, Sarcoma Medical Research Program
-
Biography
Jonathan C. Trent, MD, PhD, is professor of medicine, associate director for clinical research, and director of the Bone and Soft-tissue Sarcoma Group at the Sylvester Comprehensive Cancer Center, University of Miami Health System, Miami, FL. He earned his undergraduate degree in chemistry at Southeastern Oklahoma State University and his MD and PhD in cancer biology from The University of Texas Health Science Center. He completed an internship and residency in internal medicine at The University of Texas Health Science Center and a fellowship in medical oncology at The University of Texas MD Anderson Cancer Center while serving as chief fellow. Prior to joining the University of Miami Miller, he held appointments as faculty of The University of Texas Graduate School of Biomedical Sciences at Houston and associate professor of medicine in the Department of Sarcoma Medical Oncology, Division of Cancer Medicine, at The University of Texas MD Anderson Cancer Center in Houston. -
Education & Training
Education
Post Graduate Training
-
Honors & Awards
-
Research Interests
Jonathan C. Trent, MD, PhD, focuses his clinical, educational, and research efforts on GIST, chondrosarcoma, and other sarcomas. His interests include the clinical and translational research of sarcomas, the direct care of patients with sarcoma, and education about sarcoma and patient-oriented research. As Associate Director for Clinical Research, his goal is to help Sylvester faculty develop clinical trials that provide clinically effective and scientifically exciting therapy to patients with cancer. The major efforts of Dr Trent’s research focus on understanding the mechanisms of action and resistance of imatinib in GIST and other sarcomas while striving toward improved therapeutic options. His work involves the use of novel preoperative/postoperative clinical trials, prospectively acquired tumor tissue, cell lines, and archival tissue. -
Publications
Disclaimer: Information presented in this section has been consolidated using AI and machine learning technologies. While every effort has been made to ensure accuracy, errors may occur. If you identify any inaccuracies, use this link to inform our data team. Your feedback is appreciated and helps us improve the quality of our content.Professional Activities
Articles & News
Breaking Barriers to Cancer Clinical Trial Participation
How Sylvester’s Horowitz Initiative Is Advancing Sarcoma Treatment Through Clinical Trials and Precision Medicine
Sylvester Comprehensive Cancer Center Precision Medicine Conference Highlights New Pathways to Personalized Cancer Care
Disclaimer:
Information presented in this section has been consolidated using AI and machine learning technologies. While every effort has been made to ensure accuracy, errors may occur. If you identify any inaccuracies, use this link to inform our data team. Your feedback is appreciated and helps us improve the quality of our content.
Clinical Trials
Viewing 0 of 28 clinical trials.
-
This study aims to test if IDRX-42 can improve your GIST, enhance your wellbeing, and be safe and well-tolerated when compared to sunitinib. IDRX-42 and sunitinib are referred to as the study drug” in this document.
- Principal Investigator: Jonathan Trent
- Study Phase: Phase III
- Enrollment Status: Open
-
The purpose of this study is to find out if KQB198 in combination with imatinib is a tolerable and effective treatment for your cancer.
- Principal Investigator: Jonathan Trent
- Study Phase: Phase II
- Enrollment Status: Open
-
The study is being done to find the highest dose with manageable and tolerable side effects of DCC-3116 when taken in combination with ripretinib to treat your cancer and to learn how participants will tolerate DCC-3116 taken in combination with ripretinib.
- Principal Investigator: Jonathan Trent
- Study Phase: Phase I
- Enrollment Status: Not Accepting
-
To assess the efficacy of ivosidenib treatment based on tumor assessments by a BICR in Grade 1 and Grade 2 participants. PFS based on BICR assessment in Grade 1 and Grade 2 participants. Key SecondaryTo assess the efficacy of ivosidenib treatment based on tumor assessments by a BICR in all randomized participants. PFS based on BICR assessment in all randomized participants. To assess the efficacy of ivosidenib treatment basedon OS. OS in Grade 1 and Grade 2 participants, OS in all randomized participants.
- Principal Investigator: Jonathan Trent
- Study Phase: Phase III
- Enrollment Status: Open
-
This study will look at doses of an investigational drug called IDRX-42 in patients with GIST that has spread to other parts of the body and/or cannot be removed by surgery, who have previously undergone treatment with imatinib. The purpose of the study is to learn about the safety of IDRX-42, how it is tolerated, and what effect it may have on your body and the GIST tumors.
- Principal Investigator: Jonathan Trent
- Study Phase: Phase I
- Enrollment Status: Not Accepting
-
The aims of the Phase 1 part of this study are to: •Assess the safety and tolerability of the study drug at different doses by looking at side effects of the study drug•Assess the pharmacokinetics of the study drug at different doses. This is sometimes described as what the body does with the study drug – how long it takes for the study drug to be broken down in the body to release the chemotherapy part of the study drug, the amount of study drug circulating in the blood, how long the different parts of the study drug stay in the body, and how the amount measured in the blood relates to the dose that was given.•Evaluate the potential effects of the study drug on soft tissue sarcoma tumors, i.e., whether the study drug is causing the tumor to shrink, preventing the tumor from growing further, or not having any effect at all (meaning your cancer continues to get worse)
- Principal Investigator: Jonathan Trent
- Study Phase: Phase I/II
- Enrollment Status: Open
-
Primary Objective: To compare the efficacy of ripretinib vs sunitinib as measured by progression-free survival (PFS) based on independent radiologic review (IRR)Secondary:• To compare the objective response rate (ORR) by IRR of ripretinib vs sunitinib using modified Response Evaluation Criteria in Solid Tumors v1.1 – GIST-specific (mRECIST)• To compare the overall survival (OS) of ripretinib vs sunitinib
- Principal Investigator: Jonathan Trent
- Study Phase: Phase III
- Enrollment Status: Closed
-
Compassionate use of AL3818 will allow continued access to investigational drugs as it has shown stable disease or clinical benefit in an Advenchen trial. It is believed that discontinuing this study drug can potentially be life altering thus offering compassionate use.
- Principal Investigator: Jonathan Trent
- Study Phase: N/A
- Enrollment Status: Closed
-
A new drug called DCC-3009 is being developed by Deciphera Pharmaceuticals, LLC, to treat advanced Gastrointestinal Stromal Tumors (GIST) that are growing because of changes in specific genes. Genes are the instructions that tell a part of your body called a cell what to do. Cancer changes the genes so that the instructions are no longer correct. DCC-3009 is designed to block signals from genes that cause cancer to grow. DCC-3009 is an investigational drug which means that it has not been approved by the United States (US) Food and Drug Administration (FDA), or any other regulatory agency for sale or use by the public. The study is being done to:•Find the dose or doses of DCC-3009 that have manageable side effects and are most likely to stop cancer growth •To see how your body process DCC-3009
- Principal Investigator: Jonathan Trent
- Study Phase: Phase I/II
- Enrollment Status: Open
-
The purposes of this study are to determine the safe dose of ziftomenib to be used in combination with the established dose of imatinib. This will include an evaluation of side effects associated with ziftomenib in combination with imatinib. To determine if and for how long ziftomenib in combination with imatinib may slow down the growth of your cancer. As well as, to study the biology of your cancer and determine why it might or might not respond to treatment with ziftomenib in combination with imatinib.
- Principal Investigator: Jonathan Trent
- Study Phase: Phase I
- Enrollment Status: Open
-
A Phase 1, Multicenter, Open-Label, Dose Escalation and Expansion Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of Intravenously Administered FHD-609 in Subjects With Advanced Synovial Sarcoma or Advanced SMARCB1-Loss Tumors
- Principal Investigator: Jonathan Trent
- Study Phase: Phase 1
- Enrollment Status: Closed
-
This is a first-in-human (FIH), multicenter, non-randomized, open-label Phase 1/2 study to evaluate the safety,pharmacokinetics (PK) and anti-tumor activity of oral THE-630 in patients with advanced GIST. The study willbe conducted in two parts: a dose escalation phase, followed by an expansion phase.
- Principal Investigator: Jonathan Trent
- Study Phase: Phase I/II
- Enrollment Status: Closed
-
This is a 2-part study of the KIT inhibitor CGT9486 in subjects with locally advanced, metastatic, and/or unresectable GIST. Part 1 will consist of 2 evaluations: Part 1a will confirm the dose of a modified formulation of CGT9486 to be administered in combination with sunitinib for investigation in subsequent parts of this study, and Part 1b will evaluate for DDI between the selected dose of CGT9486 and sunitinib. Part 2 will consist of a randomized study of CGT9486+sunitinib vs sunitinib. To be eligible, all subjects must have received prior therapy with imatinib. In Part 1a, subjects may have received any number of prior lines of therapy; in Part 1b, subjects must have received at least 2 prior lines of therapy; in Part 2, subjects may not have received any TKI other than imatinib. Subjects randomized to receive sunitinib alone who have a confirmed progression event can crossover to receive treatment with CGT9486+sunitinib.
- Principal Investigator: Jonathan Trent
- Study Phase: Phase III
- Enrollment Status: Open
-
An Open-Label, Phase 2 Efficacy Study of Temozolomide (TMZ) In Advanced Succinate Dehydrogenase (SDH)-Mutant/Deficient Gastrointestinal Stromal Tumor (GIST)
- Principal Investigator: Jonathan Trent
- Study Phase: Phase 2
- Enrollment Status: Closed
-
A Phase 1 Study of AGEN1181, an Fc-Engineered Anti-CTLA-4 Monoclonal Antibody as Monotherapy and in Combination With AGEN2034 (Balstilimab), an Anti-PD-1 Monoclonal Antibody, in Subjects With Advanced Cancer
- Principal Investigator: Jonathan Trent
- Study Phase: Phase 1
- Enrollment Status: Not Accepting
-
This is an open label, non-randomized, parallel-arm study in patients with locally advanced unresectable or metastatic GIST (advanced GIST). Patients treatment regime with standard of care sunitinib or regorafenib will be determined by ctDNA detected KIT exon 13 and 17 mutations.
- Principal Investigator: Jonathan Trent
- Study Phase: Phase II
- Enrollment Status: Open
-
A Phase 4, Multicenter Study to Evaluate Discontinuation and Re-Treatment in Subjects With Tenosynovial Giant Cell Tumor (TGCT) Previously Treated With Pexidartinib
- Principal Investigator: Jonathan Trent
- Study Phase: Phase 4
- Enrollment Status: Closed
-
A Phase 1, Multicenter, Open-Label, Dose-Escalation and Expansion, Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity Study of Orally Administered AG-120 in Subjects With Advanced Solid Tumors, Including Glioma, With an IDH1 Mutation
- Principal Investigator: Jonathan Trent
- Study Phase: Phase 1
- Enrollment Status: Closed
-
Phase II Randomized Trial of Transoral Surgical Resection Followed by Low-Dose or Standard-Dose IMRT in Resectable p16+ Locally Advanced Oropharynx Cancer
- Principal Investigator: Jonathan Trent
- Study Phase: Phase 2
- Enrollment Status: Not Accepting
-
A Phase II Trial of Concurrent Axitinib and Pembrolizumab in Subjects With Advanced Alveolar Soft Part Sarcoma (ASPS) and Other Soft Tissue Sarcomas (STS)
- Principal Investigator: Jonathan Trent
- Study Phase: Phase 2
- Enrollment Status: Closed
-
A Phase 3, Interventional, Randomized, Multicenter, Open-Label Study of DCC-2618 vs Sunitinib in Patients With Advanced Gastrointestinal Stromal Tumors After Treatment With Imatinib
- Principal Investigator: Jonathan Trent
- Study Phase: Phase 3
- Enrollment Status: Closed
-
PrOspective Non-interventional Study in Patients With Locally Advanced or Metastatic TRK Fusion Cancer Treated With Larotrectinib
- Principal Investigator: Jonathan Trent
- Study Phase: N/A
- Enrollment Status: Not Accepting
-
The Circulating Cell-free Genome Atlas Study
- Principal Investigator: Jonathan Trent
- Study Phase: N/A
- Enrollment Status: Closed
-
A Phase 1/2 Open-label Study Investigating the Safety, Tolerability and Efficacy of ASP0739 as a Single Agent and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors Known to Express NY-ESO-1
- Principal Investigator: Jonathan Trent
- Study Phase: Phase 1/Phase 2
- Enrollment Status: Closed
-
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Pembrolizumab Versus Treatment of Physician's Choice in Participants With Advanced Endometrial Cancer
- Principal Investigator: Jonathan Trent
- Study Phase: Phase 3
- Enrollment Status: Closed
-
We are testing the safety of an investigational drug, NN3201. This drug is an antibody that is attracted to and binds with a specific protein that is more present on your cancer cells than other normal cells. In addition, the antibody also carries with it an anti-cancer drug. We think that when the antibody attaches to a cancer cell, it will release the drug into the cell and kill it. There may be adverse effects to normal cells that the antibody attaches to or if the drug is released outside of the cancer cells. We also want to find out the good and/or bad side effects it has on people with GIST, SCLC, ACC, uveal melanoma, NET, ChRCC, or ccRCC. This research study aims to determine the best dose of the study drug that is safe to use and has potential as a cancer treatment to be studied in future clinical trials.
- Principal Investigator: Jonathan Trent
- Study Phase: Phase I
- Enrollment Status: Not Accepting
-
Phase 1/2, Open-Label, Multicenter Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of an Anti-CTLA-4 Human Monoclonal Antibody (AGEN1884) in Subjects With Advanced or Refractory Cancer and in Subjects Who Have Progressed During Treatment With a PD 1/PD-L1 Inhibitor as Their Most Recent Therapy
- Principal Investigator: Jonathan Trent
- Study Phase: Phase 1/Phase 2
- Enrollment Status: Closed
-
A Phase III Study of AL3818 (Anlotinib, Catequentinib) Hydrochloride Monotherapy in Subjects With Metastatic or Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma and Synovial Sarcoma
- Principal Investigator: Jonathan Trent
- Study Phase: Phase 3
- Enrollment Status: Closed